Wegovy costs $1.1m to prevent one heart attack, stroke, or cardiovascular death

Airfinity analysis on data from the Wegovy trial on cardiovascular outcomes reveals that even after a 65% rebate on the list price, it will cost $1.1m to prevent one heart attack, stroke or cardiovascular death.

The SELECT trial found that the drug semaglutide, sold under brand names Wegovy and Ozempic, resulted in a 20% reduction in major adverse cardiovascular events (MACE) in the enrolled population.